These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31719931)

  • 1. Cyclic Stretching of Fibrotic Microtissue Array for Evaluation of Anti-Fibrosis Drugs.
    Asmani M; Kotei C; Hsia I; Marecki L; Wang T; Zhou C; Zhao R
    Cell Mol Bioeng; 2019 Oct; 12(5):529-540. PubMed ID: 31719931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanical stretch sustains myofibroblast phenotype and function in microtissues through latent TGF-β1 activation.
    Walker M; Godin M; Pelling AE
    Integr Biol (Camb); 2020 Sep; 12(8):199-210. PubMed ID: 32877929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the preclinical efficacy of anti-fibrosis agents using a force-sensing fibrosis on chip system.
    Hsia I; Asmani M; Zhao R
    Biosens Bioelectron; 2023 May; 228():115194. PubMed ID: 36933322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrotic microtissue array to predict anti-fibrosis drug efficacy.
    Asmani M; Velumani S; Li Y; Wawrzyniak N; Hsia I; Chen Z; Hinz B; Zhao R
    Nat Commun; 2018 May; 9(1):2066. PubMed ID: 29802256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrosis on a Chip for Screening of Anti-Fibrosis Drugs.
    Asmani M; Zhao R
    Methods Mol Biol; 2021; 2299():263-274. PubMed ID: 34028749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Mechanical Activation of Macrophages During Pulmonary Fibrogenesis for Targeted Anti-Fibrosis Therapy.
    Xu Y; Ying L; Lang JK; Hinz B; Zhao R
    bioRxiv; 2023 Jul; ():. PubMed ID: 37503121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Effects of Epithelial Cells on Fibrosis Mechanics of Microtissue and Their Spatiotemporal Dependence on the Epithelial-Fibroblast Interaction.
    Han X; Xu L; Dou T; Du R; Deng L; Wang X
    ACS Biomater Sci Eng; 2023 Aug; 9(8):4846-4854. PubMed ID: 37418666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling mechanical activation of macrophages during pulmonary fibrogenesis for targeted anti-fibrosis therapy.
    Xu Y; Ying L; Lang JK; Hinz B; Zhao R
    Sci Adv; 2024 Mar; 10(13):eadj9559. PubMed ID: 38552026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells.
    Lee MO; Jung KB; Jo SJ; Hyun SA; Moon KS; Seo JW; Kim SH; Son MY
    J Biol Eng; 2019; 13():15. PubMed ID: 30809271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary Fibrosis.
    Froese AR; Shimbori C; Bellaye PS; Inman M; Obex S; Fatima S; Jenkins G; Gauldie J; Ask K; Kolb M
    Am J Respir Crit Care Med; 2016 Jul; 194(1):84-96. PubMed ID: 26771871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
    Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K
    Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties.
    Liu M; Zheng M; Xu H; Liu L; Li Y; Xiao W; Li J; Ma E
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):214-20. PubMed ID: 26523510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation.
    Ballester B; Milara J; Cortijo J
    Oncotarget; 2020 Apr; 11(15):1306-1320. PubMed ID: 32341751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis.
    Prestigiacomo V; Weston A; Messner S; Lampart F; Suter-Dick L
    PLoS One; 2017; 12(6):e0179995. PubMed ID: 28665955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.
    Hisatomi K; Mukae H; Sakamoto N; Ishimatsu Y; Kakugawa T; Hara S; Fujita H; Nakamichi S; Oku H; Urata Y; Kubota H; Nagata K; Kohno S
    BMC Pulm Med; 2012 Jun; 12():24. PubMed ID: 22694981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
    Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
    Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.
    Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E
    Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.